HIV Scientific Papers
Ibalizumab: first global approval.
Ibalizumab in multidrug-resistant HIV - accepting uncertainty.
N Engl J Med.
Ibalizumab susceptibility in patient HIV isolates resistant to antiretrovirals [abstract].
Top Antivir Med.
"26(suppl 1):239s. Proceedings of the 2018 Conference on Retroviruses and Opportunistic Infections. "
Ibalizumab susceptibility in patient HIV isolates resistant to antiretrovirals.
Poster #561 presented at: Conference on Retroviruses and Opportunistic Infections; March 4-7, 2018; Boston, Massachusetts, USA.
Long-acting ibalizumab susceptibility in multi-drug resistant HIV patients [abstract].
#MOPEB0352. Presented at: 9th IAS Conference on HIV Science; July 23-26 2017; Paris, France.